

## FUSIONPlex Heme v3

### Description

The FUSIONPlex Heme v3 panel is a balanced pool of gene-specific primer (GSP) oligonucleotides that is optimized for use with FUSIONPlex reagents and molecular barcode (MBC) adapters to produce targeted NGS libraries. This product insert should be used in conjunction with FUSIONPlex protocol for Illumina® (RA-DOC-047), FUSIONPlex-LAC protocol for Illumina® (RA-DOC-471), or FUSIONPlex protocol for Ion Torrent<sup>™</sup> (RA-DOC-048).

FUSIONPlex Heme v3 contains **1205** GSPs targeting **121** genes commonly mutated in hematological malignancies.

Description	Part number	Storage
FUSIONPlex Heme v3 GSP1, 8 reactions	10034041	
FUSIONPlex Heme v3 GSP2, 8 reactions	10034045	-20°C ± 10°C
10X VCP Primer Mix	SA0126	

### Recommended PCR cycling

	Step	Temperature (°C)	Time	Cycles
First PCR reaction	1	95	3 min	1
	2	95	30 sec	
	3	60	10 sec	15
	4	62	5 min (100% ramp rate)	
	5	72	3 min	1
	6	4	Hold	1

## Recommended PCR cycling (cont.)

	Step	Temperature (°C)	Time	Cycles
Second PCR reaction	1	95	3 min	1
	2	95	30 sec	
	3	60	10 sec	20†
	4	65	5 min (100% ramp rate)	
	5	72	3 min	1
	6	4	Hold	1

†The number of PCR2 cycles may be decreased if you regularly experience library yields greater than 200 nM.

## Recommended reads and multiplexing

FUSIONPlex Heme v3 libraries should be sequenced to a minimum of **3.5M reads**. Starting read depth recommendations for standard profiling may be adjusted based on user needs.

## Archer™ Analysis settings

Sequencing data should be processed using Archer Analysis (v7.5, or greater). The FUSIONPlex Heme v3 panel requires selection of the **Fusion** and (optional) **SNV/Indel** pipeline(s), found under the **RNA** Input Type (see the Archer Analysis User Guide for more details on setting up your analysis).

Processing of FUSIONPlex Heme v3 panel libraries requires a one-time upload of the Panel GTF. Files can be obtained by contacting [archer-tech@idtdna.com](mailto:archer-tech@idtdna.com).

## Assay targets

Gene	Accession	Exon	Assay Type	Description**
<i>ABL1</i>	NM_005157	–	Expression Imbalance	–
<i>ABL1</i>	NM_005157	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11	Fusion	5'
<i>ABL1</i>	NM_005157	4, 5, 6	Mutation	Full exon coverage including, p.Y253–p.E255, p.V299, p.T315–p.F317, p.M351–p.F359

Gene	Accession	Exon	Assay Type	Description**
<i>ABL2</i>	NM_005158	2, 3, 4, 5, 6, 7, 8	Fusion	5'
<i>ALK</i>	NM_004304	2, 4, 6, 8, 10, 12, 13, 14, 16, 17, 18, 19, intron19, 20, mid-exon20, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29	Fusion, ALK ATIV, Internal deletion (ALKΔ2–17, ALKΔ2–3), Expression	5'
<i>ALK</i>	NM_004304	1, 2	Internal deletion (ALKΔ2–17, ALKΔ2–3)	3'
<i>ALK</i>	NM_004304	21, 22, 23, 24, 25	Mutation	Full exon coverage including p.P1153–p.C1156, p.F1174, p.L1196–p.S1206, p.G1269
<i>ALK</i>	NM_004304	9, 12, 16, 20	Mutation	Hotspot coverage including p.V597, p.H694, p.G881, p.K1062
<i>BCL11B</i>	NM_138576	1, 2, 3, 4	Fusion, Expression	5'
<i>BCL11B</i>	NM_138576	2, 3	Fusion, Expression	3'
<i>BCL2</i>	NM_000633	*1, 2, 3	Fusion, Expression	3'
<i>BCL2</i>	NM_000633	1*, 2, 3*, mid exon 3	Fusion, Expression	5'
<i>BCL2</i>	NM_000633	2	Mutation	p.F104
<i>BCL3</i>	NM_005178	–	Expression	–
<i>BCL6</i>	NM_001706	2, 3, 4, 5, 8, 9	Fusion, Expression	5'
<i>BCR</i>	NM_004327	1, 2, 3, 4, 8, 12, 13, 14, 15, 16	Fusion	3'
<i>BIRC3</i>	NM_182962	4, 5, 6, 7, 8	Fusion, Expression	3'
<i>BIRC3</i>	NM_182962	9	Mutation	p.Q547
<i>BRAF</i>	NM_004333	1, 2, 3, 7, 8, 10, 13, 14, 18	Fusion, Kinase Domain Duplication, BRAFΔ2–10, BRAFΔ4–10, BRAFΔ2–8, BRAFΔ3–8, BRAFΔ4–8, Expression	3'
<i>BRAF</i>	NM_004333	2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 15, 16	Fusion, Kinase Domain Duplication, BRAFΔ2–10, BRAFΔ4–10, BRAFΔ2–8, BRAFΔ3–8, BRAFΔ4–8, Expression	5'
<i>BRAF</i>	NM_004333	11, 15	Mutation	Full exon coverage including p.V600

Gene	Accession	Exon	Assay Type	Description**
<i>BTK</i>	NM_000061	11, 15, 16	Mutation	p.C481, p.T474, p.L528, p.T316, p.V537
<i>CARD11</i>	NM_032415	5, 6	Mutation	p.D230 p.K215T
<i>CBFB</i>	NM_022845	4, 5	Fusion	3'
<i>CCND1</i>	NM_053056	2, 3, 4, 5	Fusion, Expression	5'
<i>CCND1</i>	NM_053056	1, 2, 3, 4, mid-exon5*	Fusion, Expression	3'
<i>CCND1</i>	NM_053056	1	Mutation	p.E36, p.V42-p.C47
<i>CCND2</i>	NM_001759	–	Expression	–
<i>CCND3</i>	NM_001760	2, 3, 4, 5	Fusion, Expression	5'
<i>CCND3</i>	NM_001760	2, 4	Fusion, Expression	3'
<i>CD274</i>	NM_014143	–	Expression	–
<i>CD28</i>	NM_006139	2, 4	Fusion	5'
<i>CDK6</i>	NM_001259	1, 2, 3, 4	Fusion, Expression	3'
<i>CDKN2A</i>	NM_000077	–	Expression	–
<i>CEBPA</i>	NM_004364	1	Mutation	Full exon coverage
<i>CEBPD</i>	NM_005195	–	Expression	–
<i>CEBPE</i>	NM_001805	–	Expression	–
<i>CEBPG</i>	NM_001806	–	Expression	–
<i>CHD1</i>	NM_001270	2*, 3	Fusion	5'
<i>CHIC2</i>	NM_012110	1, 2, 3	Fusion	3'
<i>CIITA</i>	NM_000246	1, 2	Fusion	3'
<i>CREBBP</i>	NM_004380	–	Expression	–
<i>CREBBP</i>	NM_004380	16, 20, 26, 30	Mutation	p.P1053, p.C1240, p.R1446, p.S1680-p.L1681
<i>CRLF2</i>	NM_022148	–	Expression	–

Gene	Accession	Exon	Assay Type	Description**
<i>CRLF2</i>	NM_022148	1*	Fusion	5'
<i>CRLF2</i>	NM_022148	6	Mutation	p.F232
<i>CSF1R</i>	NM_005211	9, 10, 11, 12, 13, 14	Fusion	5'
<i>CTLA4</i>	NM_005214	–	Expression	–
<i>DDX41</i>	NM_016222	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17	Fusion, Expression	3'
<i>DEK</i>	NM_003472	2, 3	Fusion	3'
<i>DUSP22</i>	NM_020185	1, 2	Fusion	3'
<i>EBF1</i>	NM_024007	10, 11, 12, 13, 14, 15	Fusion	3'
<i>EIF4A1</i>	NM_001416	2, 3	Fusion	5'
<i>EPOR</i>	NM_000121	6, 7, 8	Fusion	3'
<i>ERG</i>	NM_004449	2*, 3*, 4, 5, 6, 7, 8, 9, 10, 11	Fusion	5'
<i>ETV6</i>	NM_001987	2, 3, 4, 5, 6, 7	Fusion	5'
<i>ETV6</i>	NM_001987	1, 2, 3, 4, 5, 6	Fusion	3'
<i>ETV6</i>	NM_001987	3	Mutation	p.Y104–p.R105
<i>FGFR1</i>	NM_023110	2*, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18	Fusion	5'
<i>FGFR1</i>	NM_023110	12, 17	Fusion	3'
<i>FGFR1</i>	NM_023110	4, 12, 13, 14	Mutation	Hotspot coverage including p.T141, p.V561, p.N546, p.K656
<i>FGFR2</i>	NM_000141	2*, 3, 5, 6, 7, 8, 9, 10	Fusion	5'
<i>FGFR2</i>	NM_000141	11, 16, 17, 18	Fusion	3'
<i>FGFR2</i>	NM_000141	2, 7, 9, 12, 13, 14	Mutation	p.R6, p.S252–p.P253, p.G305, p.Y375–V395, p.I547–p.N549, p.V564, p.A648–p.K659
<i>FGFR3</i>	NM_000142	3, 5, 8, 10, 11, 12, 13, 14	Fusion	5'
<i>FGFR3</i>	NM_000142	16, 17, intron17, mid–exon18	Fusion	3'

Gene	Accession	Exon	Assay Type	Description**
<i>FGFR3</i>	NM_000142	7, 9, 13, 14, 16	Mutation	Hotspot coverage including p.R248, p.S249, p.G370, p.S371, p.Y373, p.G380, p.R399, p.V555, p.D641, p.K650, p.G697, p.K715
<i>FLT3</i>	NM_004119	13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24	Fusion, Internal Tandem Duplication, Expression	5'
<i>FLT3</i>	NM_004119	8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21	Mutation	Full exon coverage including p.F590–p.N609, p.D835–p.S838
<i>FOXP1</i>	NM_032682	–	Expression	–
<i>GLIS2</i>	NM_032575	2, 3	Fusion	5'
<i>ID4</i>	NM_001546	–	Expression	–
<i>IDH1</i>	NM_005896	3, 4	Mutation	Full exon coverage including p.R132
<i>IDH2</i>	NM_002168	4, 6	Mutation	Full exon coverage including p.R140 and p.R172
<i>IKZF1</i>	NM_006060	1*, 2*, 3, 4, 5, 6, 7, 8	Fusion, Exon Skipping	5'
<i>IKZF1</i>	NM_006060	1*, 2, 3, 5	Fusion, Exon Skipping	3'
<i>IKZF2</i>	NM_016260	3, 4, 6	Fusion	3'
<i>IKZF3</i>	NM_012481	2, 3, 4, 5, 6, 7	Fusion	3'
<i>IKZF3</i>	NM_012481	5	Mutation	p.L162
<i>IL2RB</i>	NM_000878	2	Fusion	5'
<i>IRF4</i>	NM_002460	–	Expression	–
<i>IRF8</i>	NM_002163	–	Expression	–
<i>JAK1</i>	NM_002227	5, 14, 15, 16, 17	Mutation	Full exon coverage including, p.V658, p.S703, p.R724, p.A634D, p.V658, p.R724
<i>JAK1</i>	NM_002227	13	Mutation	p.R629_D630del
<i>JAK2</i>	NM_004972	6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22	Fusion	5'
<i>JAK2</i>	NM_004972	9, 10, 11, 12, 18, 19, 20, 22	Fusion	3'

Gene	Accession	Exon	Assay Type	Description**
<i>JAK2</i>	NM_004972	12, 13, 14, 15, 16, 19, 20, 21, 22	Mutation	Full exon coverage including p.F537–F547, p.V617–C618, p.L681–R683, p.L855, p.V863, p.A880, p.V911, p.M929–R938, p.I960, p.R980–E985, p.D994
<i>JAK3</i>	NM_000215	22, 23	Fusion	3'
<i>JAK3</i>	NM_000215	10, 11, 12, 17, 18, 19	Fusion	5'
<i>JAK3</i>	NM_000215	4, 13, 15, 16, 18	Mutation	Full exon coverage including p.A572–A573, p.R657, p.S789
<i>JAK3</i>	NM_000215	11	Mutation	p.M511
<i>KAT6A</i>	NM_006766	13, 14, 15, 16, 17*	Fusion	3'
<i>KIT</i>	NM_000222	2, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18	Mutation	Full exon coverage including p.T417–p.D419, p.T670, p.R796, p.D816, p.N822–p.V825
<i>KLF2</i>	NM_016270	2, 3	Fusion	5'
<i>KMT2A</i>	NM_005933	4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35	Fusion	3'
<i>KMT2A</i>	NM_005933	2, 3	Fusion	5'
<i>LYN</i>	NM_001111097	2*, 3, 4, 5, 6, 7, 8	Fusion	5'
<i>MALT1</i>	NM_006785	9	Fusion	3'
<i>MECOM</i>	NM_004991	1*, 2, 3, 4, 5, 8	Fusion, Expression	5'
<i>MEF2C</i>	NM_002397	5	Fusion	3'
<i>MEF2D</i>	NM_005920	3, 4, 5, 6, 7, 9	Fusion	3'
<i>MEN1</i>	NM_130799	2, 3, 4, 5, 6, 7, 8, 9, 10	Mutation	Full exon coverage
<i>MKL1</i>	NM_020831	4, 5, 6	Fusion	5'
<i>MLF1</i>	NM_022443	2, 3, 4	Fusion	5'
<i>MLLT10</i>	NM_004641	2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18	Fusion	5'

Gene	Accession	Exon	Assay Type	Description**
<i>MLLT10</i>	NM_004641	7, 8, 9, 10	Fusion	3'
<i>MLLT4</i>	NM_001040000	2	Fusion	5'
<i>MUC1</i>	NM_002456	–	Expression	–
<i>MYC</i>	NM_002467	1, 2	Fusion, Expression	3'
<i>MYC</i>	NM_002467	1, 2, 3	Fusion, Expression	5'
<i>MYH11</i>	NM_002474	–	Expression Imbalance	–
<i>MYH11</i>	NM_002474	5, 6, 7, 8, 9, 10, 11, 14, 15, 16, 18, 19, 20, 33	Fusion	5'
<i>NF1</i>	NM_000267	14	Fusion	3'
<i>NF1</i>	NM_000267	36	Fusion	5'
<i>NFKB2</i>	NM_002502	14, 15, 16, 17, 18, 19, 20, 21	Fusion	3'
<i>NOTCH1</i>	NM_017617	34	Exon Skipping	N/A
<i>NOTCH1</i>	NM_017617	2, 4, 24, 29, 30, 31	Fusion	3'
<i>NOTCH1</i>	NM_017617	5, 24, 25, 26, 27, 28, 29	Fusion	5'
<i>NOTCH1</i>	NM_017617	26, 27, 34	Mutation	p.L1574, p.V1578, p.L1585, p.F1592–p.L1593, p.R1598– p.L1600, p.L1678–p.I1680, p.P2514–p.E2515, p.P2525
<i>NPM1</i>	NM_002520	11	Mutation	p.W22–W290
<i>NTRK1</i>	NM_001007792	1, 2	Fusion	5'
<i>NTRK1</i>	NM_002529	15, 16, 17	Fusion	3'
<i>NTRK1</i>	NM_002529	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14	Fusion	5'
<i>NTRK1</i>	NM_002529	13, 14, 15, 16, 17	Mutation	Full kinase domain coverage for resistance mutations including p.G595
<i>NTRK2</i>	NM_006180	4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18	Fusion	5'
<i>NTRK2</i>	NM_006180	11, 14	Fusion	3'

Gene	Accession	Exon	Assay Type	Description**
<i>NTRK2</i>	NM_006180	16, 17, 18, 19, 20, 21	Mutation	Full kinase domain coverage for resistance mutations
<i>NTRK3</i>	NM_001007156	15	Fusion	5'
<i>NTRK3</i>	NM_002530	3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16	Fusion	5'
<i>NTRK3</i>	NM_002530	13, 14, 15, 17	Fusion	3'
<i>NTRK3</i>	NM_002530	15, 16, 17, 18, 19	Mutation	Full kinase domain coverage for resistance mutations detection including p.F617, p.G623, p.G696
<i>NUP214</i>	NM_005085	17, 18, 19	Fusion	5'
<i>NUP98</i>	NM_016320	8, 9, 10, 11, 12, 13, 14, 15, 16, 17	Fusion	3'
<i>NUP98</i>	NM_016320	12, 13	Fusion	5'
<i>NUTM1</i>	NM_175741	2*, 3, mid-exon3, 4, 5, mid-exon6, 6	Fusion	5'
<i>P2RY8</i>	NM_178129	1	Fusion	3'
<i>PAG1</i>	NM_018440	2	Fusion	5'
<i>PAX5</i>	NM_016734	6, 7, 8	Fusion	5'
<i>PAX5</i>	NM_016734	1, 4, 5, 6, 7, 8	Fusion	3'
<i>PAX5</i>	NM_016734	3	Mutation	p.P80
<i>PDCD1</i>	NM_005018	–	Expression	–
<i>PDCD1LG2</i>	NM_025239	3, 5, 6	Fusion	3'
<i>PDCD1LG2</i>	NM_025239	1*, 2, 3	Fusion	5'
<i>PDGFRA</i>	NM_006206	9, 10, 11, 12, mid-exon12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23	Fusion,PDGFRAΔi8,9	5'
<i>PDGFRA</i>	NM_006206	7	Fusion,PDGFRAΔi8,9	3'
<i>PDGFRA</i>	NM_006206	12, 14, 18	Mutation	Full exon coverage including p.D842
<i>PDGFRA</i>	NM_006206	6, 15	Mutation	Hotspot coverage including p.Y288, p.T674

Gene	Accession	Exon	Assay Type	Description**
<i>PDGFRB</i>	NM_002609	8, 9, 10, 11, 12, mid-exon 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23	Fusion	5'
<i>PICALM</i>	NM_007166	16, 17, 18, 19	Fusion	3'
<i>PLCG2</i>	NM_002661	19, 20, 24	Mutation	p.R665, p.L845, p.S707
<i>PML</i>	NM_002675	2, 3, 4, 5, 6, 7*	Fusion	3'
<i>PML</i>	NM_002675	2	Fusion	5'
<i>PML</i>	NM_002675	3	Mutation	p.C212–p.S220
<i>PRDM16</i>	NM_022114	1*, 2, 3, 4	Fusion	5'
<i>PTK2B</i>	NM_173176	2*, 3, 4, 5, 6, 7, 8	Fusion	5'
<i>RARA</i>	NM_000964	–	Expression Imbalance	–
<i>RARA</i>	NM_000964	1*, 2*, 3, 4, 5, 6, 8, 9	Fusion	5'
<i>RARA</i>	NM_000964	5, 7, 9	Mutation	p.E197, p.R272, p.T283–p.M284, p.L290–p.M297, p.R394, p.Q411
<i>RBM15</i>	NM_022768	1	Fusion	3'
<i>RET</i>	NM_020630	2, 4, 6, 8, 9, 10, 11, mid-exon11, 12, 13, 14	Fusion	5'
<i>RET</i>	NM_020630	8, 10, 11, 13, 14, 15, 16	Mutation	Hotspot coverage including p.A883, p.M918
<i>ROS1</i>	NM_002944	–	Expression Imbalance	–
<i>ROS1</i>	NM_002944	2, 4, 7, 31, 32, 33, 34, 35, 36, 37	Fusion	5'
<i>ROS1</i>	NM_002944	38, 39, 40	Mutation	Hotspot coverage including p.G2032, p.C2060, p.V2098, p.G2101
<i>RUNX1</i>	NM_001122607	1, 5	Mutation	N/A
<i>RUNX1</i>	NM_001754	–	Expression Imbalance	–
<i>RUNX1</i>	NM_001754	2, 3, 4, 5, 6, 7, 8	Fusion	3'
<i>RUNX1</i>	NM_001754	2, 3, 4, 5, 6, 7, 8, 9	Fusion	5'

Gene	Accession	Exon	Assay Type	Description**
<i>RUNX1</i>	NM_001754	2, 3, 4, 5, 6, 7, 8, 9	Mutation	N/A
<i>RUNX1T1</i>	NM_001198679	–	Expression Imbalance	–
<i>RUNX1T1</i>	NM_001198679	2, 3	Fusion	5'
<i>SEMA6A</i>	NM_020796	1*, 2	Fusion	3'
<i>SETBP1</i>	NM_015559	2*, 3	Fusion	5'
<i>SETBP1</i>	NM_015559	4	Mutation	p.D868–p.I871
<i>SETD2</i>	NM_014159	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12	Fusion	3'
<i>SF3B1</i>	NM_012433	14, 15, 16	Mutation	p.E622–p.N626, p.H662– p.K666, p.K700, p.I704, p.G740, p.G742
<i>SH2B3</i>	NM_005475	2, 3, 6, 7	Mutation	p.E208, p.M211fs, p.D231– p.D234, p.M268, p.R392, p.E400, p.L438
<i>STAT3</i>	NM_003150	21, 23	Fusion	3'
<i>STAT3</i>	NM_003150	21	Mutation	p.Y640–p.N647, p.D661
<i>STIL</i>	NM_003035	1*, 2	Fusion	3'
<i>TAL1</i>	NM_001290404	2, 3	Fusion	5'
<i>TAL1</i>	NM_003189	–	Expression	–
<i>TAL1</i>	NM_003189	2, 4	Fusion	5'
<i>TCF3</i>	NM_003200	11, 12, 13, 14, 15, 16, 17, 18	Fusion	3'
<i>TFG</i>	NM_006070	2, 3, 4, 5, 6, 7, 8	Fusion	3'
<i>TFG</i>	NM_006070	6	Fusion	5'
<i>TP53</i>	NM_000546	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11	Mutation	Full exon coverage
<i>TP53</i>	NM_001276695	10	Mutation	Full exon coverage
<i>TP53</i>	NM_001276696	10	Mutation	Full exon coverage
<i>TP63</i>	NM_003722	3, 4, 5	Fusion	5'
<i>TSLP</i>	NM_033035	1, 3	Fusion	3'

Gene	Accession	Exon	Assay Type	Description**
<i>TSLP</i>	NM_033035	1, 2, 4	Fusion	5'
<i>TYK2</i>	NM_003331	16, 18, 19	Fusion	5'
<i>TYK2</i>	NM_003331	7	Mutation	p.W327
<i>UBA1</i>	NM_003334	3	Mutation	p.M41
<i>UBTF</i>	NM_014233	14, 15, 16, 17, 18, 19, 20	Fusion, Internal Tandem Duplication, Expression	3'
<i>UBTF</i>	NM_014233	14	Fusion, Internal Tandem Duplication, Expression	5'
<i>UBTF</i>	NM_014233	9, 13	Mutation	Full exon coverage
<i>XPO1</i>	NM_003400	15	Mutation	p.E571
<i>ZCCHC7</i>	NM_032226	2*, 3, 4	Fusion	5'
<i>ZCCHC7</i>	NM_032226	1*, 2, 3	Fusion	3'
<i>ZNF384</i>	NM_001039920	5	Fusion	5'
<i>ZNF384</i>	NM_001135734	8	Fusion	5'
<i>ZNF384</i>	NM_133476	2*, 3, 4, 5, 6, 7, 8	Fusion	5'

\*Indicates exons that are entirely untranslated region (UTR), or for which the UTR is targeted.

\*\*The mutations listed under the Description column are targeted by the assay design. *De Novo* RNA SNV/Indel and Internal Tandem Duplication mutation detection are not supported on the Ion Torrent Sequencing System.

†ALK-AT1 currently requires review outside of Archer Analysis.

Note: Fusions involving *BCR* and *TCR* loci, including *IGH*, *IGL*, and *IGK*, are targeted for expression and may not be explicitly called as a fusion because these often do not result in chimeric transcripts. For the “Expression” assay type, unique molecules originating from probes across these genes can be counted and normalized to target control genes to enable relative expression level detection. Results are visualized in Archer Analysis.

## SNPs and sites targeted for sample tracking

rs560681	rs430046	rs987640	rs10776839	rs12393891
rs740598	rs8078417	rs6444724	rs6530357	chrX 4429309
rs1498553	rs9951171	rs6811238	rs5971553	chrX 11314433
rs10773760	rs576261	rs13182883	rs5953060	chrY 6738552
rs1058083	rs1109037	rs214955	rs6524626	chrY 19490214
rs4530059	rs1523537	rs321198	rs5940270	
rs1821380	rs221956	rs4606077	rs722847	

SNPs may be used in combination to uniquely tag and track samples over time. Contact [archer-tech@idtdna.com](mailto:archer-tech@idtdna.com) for further details.

## Limitations of use

**For research use only. Not for use in diagnostic procedures.** Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

Safety data sheets pertaining to this product are available upon request.

This product or service is licensed under one or more of the following U.S. Patents: 8,835,358; 9,290,808; 9,290,809; 9,315,857; 9,708,659; and 9,816,137 owned by BD and is licensed solely for the use described in the associated product literature. No other rights, implied or otherwise, are granted to purchaser hereunder. Purchaser agrees, by way of example and not limitation, not to use this product to trace back the origin of a nucleic acid to an individual cell as a discrete entity (e.g., single cell analysis).

© 2026 Integrated DNA Technologies, Inc. All rights reserved. FUSIONPlex, VARIANTPlex, LIQUIDPlex, IMMUNOVERSE, Archer Analysis, and Archer Assay Marketplace are trademarks of Integrated DNA Technologies, Inc. All other marks are the property of their respective owners. For specific trademark and licensing information, see [www.idtdna.com/trademarks](http://www.idtdna.com/trademarks).

## Revision History

Document Number	Date	Description of change
RA-DOC-650/REV01	March 2026	Initial release